Is Bristol-Myers Squibb All Set for a Strong 2014?

After a great 2013, can Bristol-Myers Squibb (NYSE: BMY) perform as well in 2014?

Mar 1, 2014 at 3:30PM

Bristol-Myers Squibb (NYSE:BMY) enjoyed a scintillating year in 2013, as its shares posted gains of 66% -- well ahead of the S&P 500's return of 32%.

A key reason for this success could have been that the market is gradually warming to its new strategy, with Bristol-Myers Squibb shifting away from being a producer of mass-market drugs to a specialist, niche player. Furthermore, its results from the fourth quarter of 2013 showed that the company continues to make encouraging progress.

Although fourth-quarter net profit fell by 21.5%, this was due to the comparator results (the fourth quarter of 2012) having a $411 million tax benefit resulting from the writing off of a failed experimental medicine. The results, though, were ahead of Wall Street expectations and showed top-line growth of 6% for the quarter. However, after such an impressive year, can Bristol-Myers Squibb do more of the same in 2014?

Upbeat news flow
Recent pipeline developments have been encouraging for Bristol-Myers Squibb. For instance, it reported this week that the FDA has granted investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation for use as a combination therapy in the treatment of hepatitis C. This is positive news for the company and is based on data from its ongoing Phase 3 clinical trial program, with Breakthrough Therapy Designation likely to mean expedited development and review of the drug.

It also announced this week that the FDA has approved a drug developed alongside AstraZeneca (NYSE:AZN) to treat rare and potentially fatal disorders involving the loss of body fat. The drug, Myalept, has been developed in a partnership between Bristol-Myers Squibb and AstraZeneca and has been approved as a replacement therapy to treat complications caused by leptin hormone deficiency in patients with congenital generalized lipodystrophy. This involves a loss of fat tissue, leading to low levels of leptin, which can ultimately cause diabetes and pancreatitis.

In addition, Bristol-Myers Squibb also announced (alongside its partner, Pfizer (NYSE:PFE)) the results of a sub analysis of the phase 3 Aristotle trial in relation to patients with nonvalvular atrial fibrillation, or NVAF, which found that their Eliquis treatment was more effective than warfarin in reducing the risk of stroke and in reducing mortality across age groups. It was also associated with less bleeding and less intracranial haemorrhage, regardless of age. Again, this is encouraging news flow for Bristol-Myers Squibb and Pfizer, with the drug already approved to reduce the risk of stroke and systemic embolism in patients with NVAF in the U.S. and the European Union.

Elsewhere in pharmaceuticals
Of course, Bristol-Myers Squibb, Pfizer and AstraZeneca aren't the only stocks to have experienced positive news flow. Pharmaceutical peer, Eli Lilly (NYSE:LLY), just last week said that a once-weekly drug for type 2 diabetes was comparable to Novo Nordisk's once-daily treatment, Victoza, in reducing a measure of blood sugar in a patient study. Indeed, Eli Lilly hopes that this development could give it a competitive advantage, with sales of the drug having the potential to reach $2 billion, should it be approved by regulators.

Above-average yields
Despite shares increasing by 66% in 2013, Bristol-Myers Squibb continues to offer an above-average yield. Shares currently yield 2.6%, which is ahead of the S&P 500 yield of 1.95%. It also compares reasonably well to the yields offered by Eli Lilly and Pfizer, with the sector peers yielding 3.3% and 2.7% respectively.

For this reason, it looks as though all three stocks could have a promising year. Indeed, they are all ahead of the S&P thus far in 2014, with Bristol-Myers Squibb at the rear of the pack (up 1.5%, while Pfizer is up 5.2% and Eli Lilly has gained 16.8%, with the S&P 500 flat in 2014). However, because of its underperformance versus its peers in the first two months of the year, Bristol-Myers Squibb could reduce the gap and continue to outperform the wider index during the remainder of the year. Indeed, it looks all-set to have a strong 2014.

More great yielding stocks
One of the dirty secrets that few finance professionals will openly admit is that dividend stocks as a group handily outperform their non-dividend-paying brethren. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Peter Stephens owns shares of AstraZeneca. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers